Trade FibroGen, Inc - FGEN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.41 |
| Open | 0.41 |
| 1-Year Change | -57.29% |
| Day's Range | 0.4 - 0.45 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | 0.44 | 0.03 | 7.32% | 0.41 | 0.45 | 0.40 |
| Sep 12, 2024 | 0.41 | 0.03 | 7.89% | 0.38 | 0.41 | 0.38 |
| Sep 11, 2024 | 0.37 | -0.01 | -2.63% | 0.38 | 0.38 | 0.35 |
| Sep 10, 2024 | 0.38 | 0.01 | 2.70% | 0.37 | 0.40 | 0.34 |
| Sep 9, 2024 | 0.37 | 0.00 | 0.00% | 0.37 | 0.38 | 0.35 |
| Sep 6, 2024 | 0.37 | -0.02 | -5.13% | 0.39 | 0.40 | 0.36 |
| Sep 5, 2024 | 0.39 | 0.03 | 8.33% | 0.36 | 0.40 | 0.36 |
| Sep 4, 2024 | 0.38 | 0.03 | 8.57% | 0.35 | 0.39 | 0.35 |
| Aug 27, 2024 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
| Aug 26, 2024 | 0.39 | 0.01 | 2.63% | 0.38 | 0.40 | 0.38 |
| Aug 23, 2024 | 0.39 | 0.01 | 2.63% | 0.38 | 0.39 | 0.38 |
| Aug 22, 2024 | 0.39 | 0.00 | 0.00% | 0.39 | 0.39 | 0.39 |
| Aug 21, 2024 | 0.38 | -0.01 | -2.56% | 0.39 | 0.40 | 0.37 |
| Aug 20, 2024 | 0.39 | 0.04 | 11.43% | 0.35 | 0.41 | 0.35 |
| Aug 19, 2024 | 0.35 | 0.00 | 0.00% | 0.35 | 0.36 | 0.34 |
| Aug 13, 2024 | 0.38 | -0.01 | -2.56% | 0.39 | 0.40 | 0.38 |
| Aug 12, 2024 | 0.38 | -0.01 | -2.56% | 0.39 | 0.39 | 0.38 |
| Aug 9, 2024 | 0.39 | -0.01 | -2.50% | 0.40 | 0.40 | 0.39 |
| Aug 8, 2024 | 0.41 | -0.05 | -10.87% | 0.46 | 0.47 | 0.39 |
| Aug 7, 2024 | 0.44 | -0.01 | -2.22% | 0.45 | 0.48 | 0.44 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
FibroGen, Inc Company profile
About FibroGen Inc
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.
| Industry: | Biotechnology & Medical Research (NEC) |
409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US
News
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com